Brilli · European review for medical and pharmacological sciences 2018 · double-blind crossover trial and ex vivo study · n=?

Magnesium bioavailability after administration of sucrosomial® magnesium: results of an ex-vivo study and a comparative, double-blinded, cross-over study in healthy subjects.

Cited 14 times in the scientific literature.

Level 2 - randomized trial

Double-blind crossover trial in healthy human subjects with an accompanying ex vivo model

PubMed 29630135 · doi:10.26355/eurrev_201803_14605 · record verified 2026-08-29

What was done

Researchers compared the intestinal absorption and bioavailability of Sucrosomial magnesium against magnesium oxide, magnesium citrate, and magnesium bisglycinate. In an ex vivo phase, isolated rat intestinal mucosa was used to measure absorption rates across two concentrations (32.9 mg/ml and 329 mg/ml). In a human trial, healthy subjects ingested single 350 mg magnesium doses of each formulation in a double-blind, repeated crossover design with a 1-week washout between conditions. Blood, red blood cell, and urinary magnesium concentrations were tracked over 24 hours.

What was found

The abstract reports statistical comparisons but provides no numerical values, baseline concentrations, or exact p-values. Ex vivo absorption was reported as faster and higher for Sucrosomial magnesium than magnesium oxide. In human participants, the 0-to-24-hour increase in magnesium concentration was statistically significantly higher in blood and urine for Sucrosomial magnesium compared to magnesium oxide, and statistically significantly higher in red blood cells compared to magnesium bisglycinate.

Why it matters

Sucrosomial encapsulation may enhance oral magnesium absorption relative to common inorganic and chelated preparations, potentially allowing lower doses or improved tissue delivery.

Limits

The abstract omits human participant count (n), baseline demographics, exact pharmacokinetic values (AUC, Cmax), and numerical variance data. Only single-dose 24-hour kinetics were evaluated in healthy individuals, leaving long-term tissue repletion, tolerability, and clinical outcomes in magnesium-deficient populations unaddressed.

Cited by